S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
S&P 500   3,325.54 (+0.11%)
DOW   29,160.09 (-0.09%)
QQQ   224.59 (+0.32%)
AAPL   319.23 (+0.48%)
FB   219.76 (-0.70%)
MSFT   166.72 (+0.62%)
GOOGL   1,484.69 (+0.04%)
AMZN   1,884.58 (-0.15%)
CGC   24.56 (+1.82%)
NVDA   252.86 (+1.12%)
BABA   219.13 (-1.46%)
MU   59.20 (+0.05%)
GE   11.77 (+3.52%)
TSLA   572.20 (+0.46%)
AMD   51.71 (+0.54%)
T   38.63 (-1.05%)
ACB   2.07 (+1.47%)
F   9.14 (-0.22%)
NFLX   349.60 (+7.24%)
BAC   34.12 (-0.70%)
DIS   142.20 (-1.26%)
GILD   63.94 (+0.80%)
Log in
(Ad)
One of the best ways to double, if not triple your investment in 2020 will be found in tech stocks. Especially those involved with the 5G rollout, where we're still finding undervalued opportunities. In our latest special report, we detail these and other hot tech stocks that should be part of your portfolio right now.

NASDAQ:ICCC - ImmuCell Stock Price, Forecast & News

$5.19
-0.06 (-1.14 %)
(As of 01/23/2020 04:00 PM ET)
Today's Range
$5.13
Now: $5.19
$5.50
50-Day Range
$4.90
MA: $5.14
$5.92
52-Week Range
$4.70
Now: $5.19
$8.28
Volume61,100 shs
Average Volume205,293 shs
Market Capitalization$37.42 million
P/E RatioN/A
Dividend YieldN/A
Beta1.26
ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company offers First Defense, an orally delivered scours preventive product for calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing Re-Tain, a Nisin-based treatment of subclinical mastitis in lactating dairy cows; and offers Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products through animal health distributors. The company was founded in 1982 and is headquartered in Portland, Maine.

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ICCC
CUSIPN/A
Phone207-878-2770

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.99 million
Book Value$3.96 per share

Profitability

Net Income$-2,320,000.00

Miscellaneous

Employees47
Market Cap$37.42 million
Next Earnings Date2/18/2020 (Confirmed)
OptionableNot Optionable

Receive ICCC News and Ratings via Email

Sign-up to receive the latest news and ratings for ICCC and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

Inside THIS MYSTERIOUS BOOK is 100 life-changing ways to maximize your retirement benefits...

My Wife and I Got $17,000 Right Off the Bat! "Excellent book! Making my wife and I almost $17,000 right off the bat and increasing our retirement income by well over a third. Purchase of this book was my biggest and best investment ever!"-- Rick M.

ImmuCell (NASDAQ:ICCC) Frequently Asked Questions

What is ImmuCell's stock symbol?

ImmuCell trades on the NASDAQ under the ticker symbol "ICCC."

How were ImmuCell's earnings last quarter?

ImmuCell Co. (NASDAQ:ICCC) announced its quarterly earnings data on Monday, November, 11th. The biotechnology company reported ($0.07) EPS for the quarter. The biotechnology company earned $2.97 million during the quarter. ImmuCell had a negative net margin of 15.64% and a negative return on equity of 7.35%. View ImmuCell's Earnings History.

When is ImmuCell's next earnings date?

ImmuCell is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for ImmuCell.

How can I listen to ImmuCell's earnings call?

ImmuCell will be holding an earnings conference call on Tuesday, February 18th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Has ImmuCell been receiving favorable news coverage?

News coverage about ICCC stock has been trending somewhat negative on Thursday, according to InfoTrie. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ImmuCell earned a coverage optimism score of -1.8 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for ImmuCell.

Are investors shorting ImmuCell?

ImmuCell saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 2,700 shares, an increase of 575.0% from the December 15th total of 400 shares. Based on an average daily trading volume, of 11,000 shares, the short-interest ratio is currently 0.2 days. Approximately 0.1% of the shares of the company are short sold. View ImmuCell's Current Options Chain.

Who are some of ImmuCell's key competitors?

What other stocks do shareholders of ImmuCell own?

Who are ImmuCell's key executives?

ImmuCell's management team includes the folowing people:
  • Mr. Michael F. Brigham, Pres, CEO, Principal Financial Officer, Treasurer, Sec. & Director (Age 58)
  • Dr. Joseph H. Crabb, VP & Chief Scientific Officer (Age 64)
  • Ms. Bobbi Jo Brockmann, VP of Sales & Marketing and Director (Age 42)
  • Ms. Elizabeth L. Williams, VP of Manufacturing Operations (Age 63)

How do I buy shares of ImmuCell?

Shares of ICCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ImmuCell's stock price today?

One share of ICCC stock can currently be purchased for approximately $5.19.

How big of a company is ImmuCell?

ImmuCell has a market capitalization of $37.42 million and generates $10.99 million in revenue each year. ImmuCell employs 47 workers across the globe.View Additional Information About ImmuCell.

What is ImmuCell's official website?

The official website for ImmuCell is http://www.immucell.com/.

How can I contact ImmuCell?

ImmuCell's mailing address is 56 EVERGREEN DR, PORTLAND ME, 04103. The biotechnology company can be reached via phone at 207-878-2770 or via email at [email protected]


MarketBeat Community Rating for ImmuCell (NASDAQ ICCC)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  113 (Vote Outperform)
Underperform Votes:  79 (Vote Underperform)
Total Votes:  192
MarketBeat's community ratings are surveys of what our community members think about ImmuCell and other stocks. Vote "Outperform" if you believe ICCC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICCC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel